17,060 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Empirical Financial Services LLC d.b.a. Empirical Wealth Management

Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 17,060 shares of the company’s stock, valued at approximately $354,000.

Several other institutional investors have also recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after buying an additional 78,543 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health during the first quarter worth $30,000. EverSource Wealth Advisors LLC raised its position in Hims & Hers Health by 273.7% during the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after acquiring an additional 687 shares in the last quarter. Amundi raised its position in Hims & Hers Health by 5.3% during the second quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after acquiring an additional 522 shares in the last quarter. Finally, California Public Employees Retirement System lifted its stake in Hims & Hers Health by 9.5% in the second quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock valued at $16,880,000 after acquiring an additional 29,471 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Activity

In other news, Director David B. Wells acquired 48,400 shares of Hims & Hers Health stock in a transaction dated Tuesday, May 26th. The stock was bought at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the completion of the acquisition, the director directly owned 224,417 shares in the company, valued at approximately $5,437,623.91. The trade was a 27.50% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $441,850.50. Following the sale, the chief operating officer directly owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 83,126 shares of company stock valued at $2,711,339. Company insiders own 11.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on HIMS shares. Bank of America lifted their price objective on shares of Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a research report on Thursday, July 9th. TD Cowen cut their target price on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research note on Friday, March 27th. Truist Financial lifted their price target on Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a report on Friday, May 22nd. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $30.70.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $32.89 on Monday. The company has a market cap of $7.61 billion, a P/E ratio of -365.44, a P/E/G ratio of 92.42 and a beta of 2.35. The firm’s fifty day moving average price is $30.14 and its two-hundred day moving average price is $26.34. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. During the same quarter in the prior year, the business posted $0.20 EPS. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. Equities analysts expect that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.